




Therapeutic drugs based on naturally occurring peptides
and protein fragments offer attractive alternatives to non-peptidic drugs,
due to high and very specific activity, and in most cases, low toxicity
of these native molecules. In the past couple of decades significant efforts
were devoted in both academia and industry to optimize the in vivo biological
properties of peptidic drug leads and their peptidomimetic derivatives,
without much success. According to Chaperone's cell penetration assays,
labeled versions of the native antibacterial peptides pyrrhocoricin, drosocin
and apidaecin enter Escherichia coli cells and mouse macrophages. Therefore,
if the antibacterial peptides or their delivery units are co-synthesized
with other drug leads, pyrrhocoricin or drosocin can facilitate the penetration
of these other drug leads into mammalian cells. Ultimately this system
can be used to make any drug lead orally available. Chaperone is trying
to provide a generally applicable system for the oral delivery of peptidic
and peptidomimetic drug leads developed at other biotechnology or pharmaceutical
firms.
|
![]() |